EyePoint Pharmaceuticals, Inc. Contracts & Agreements

First Amendment to Northbridge Lease, dated September 30, 2024, by and between EyePoint Pharmaceuticals US, Inc. and 600 CPK LLC (Filed With SEC on November 7, 2024)

Memorandum of Understanding, dated August 26, 2024, by and between EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics (Filed With SEC on November 7, 2024)

Underwriting Agreement, dated October 29, 2024, by and between EyePoint Pharmaceuticals, Inc. and J.P. Morgan Securities LLC (Filed With SEC on October 31, 2024)

Severance Agreement and General Release, dated August 6, 2024, by and between EyePoint Pharmaceuticals, Inc. and Nancy S. Lurker (Filed With SEC on August 8, 2024)

EyePoint Pharmaceuticals, Inc. Amendment No 1. to 2023 Long-Term Incentive Plan (Filed With SEC on June 21, 2024)

EyePoint Pharmaceuticals, Inc. Amendment No 2. to 2019 Employee Stock Purchase Plan (Filed With SEC on June 21, 2024)

Employment Agreement, dated March 4, 2024, by and between EyePoint Pharmaceuticals, Inc. and Ramiro Ribeiro, M.D., Ph.D (Filed With SEC on May 9, 2024)

Description of Securities of EyePoint Pharmaceuticals, Inc (Filed With SEC on March 8, 2024)

Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 8, 2024)

Form of Stock Option Award for Inducement Grants to executive officer pursuant to the 2023 LTIP (Filed With SEC on March 8, 2024)

Consulting Agreement dated December 18, 2023 by and between Eyepoint Pharmaceuticals, Inc. and John Landis, PhD (Filed With SEC on March 8, 2024)

Underwriting Agreement, dated December 4, 2023, by and between EyePoint Pharmaceuticals, Inc. and J.P. Morgan Securities LLC (Filed With SEC on December 8, 2023)

Second Amendment to Employment Agreement, dated July 10, 2023, by and between EyePoint Pharmaceuticals, Inc. and Nancy S. Lurker (Filed With SEC on July 10, 2023)

Second Amendment to Employment Agreement, dated July 10, 2023, by and between EyePoint Pharmaceuticals, Inc. and Jay S. Duker (Filed With SEC on July 10, 2023)

EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan (Filed With SEC on June 21, 2023)

Product Rights Agreement, dated May 17, 2023, by and between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc (Filed With SEC on May 18, 2023)

Commercial Supply Agreement, dated May 17, 2023, by and between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc (Filed With SEC on May 18, 2023)

First Amendment to Employment Agreement, dated January 3, 2023, by and between EyePoint Pharmaceuticals, Inc. and Jay S. Duker (Filed With SEC on January 6, 2023)

First Amendment to Employment Letter Agreement, dated January 3, 2023, by and between EyePoint Pharmaceuticals, Inc. and Nancy S. Lurker (Filed With SEC on January 6, 2023)

Employment Agreement, dated January 3, 2023, by and between EyePoint Pharmaceuticals, Inc. and George O. Elston (Filed With SEC on January 6, 2023)

Employment Agreement, dated January 3, 2023, by and between EyePoint Pharmaceuticals, Inc. and Scott Jones (Filed With SEC on January 6, 2023)

EyePoint Pharmaceuticals, Inc. Amended and Restated 2016 Long Term Incentive Plan, as Amended (Filed With SEC on November 14, 2022)

Amendment #1 to Exclusive License Agreement, dated May 2, 2022, by and between EyePoint Pharmaceuticals, Inc. and Equinox Sciences, LLC (Filed With SEC on August 5, 2022)

Exclusive License Agreement, dated May 2, 2022, by and between EyePoint Pharmaceuticals, Inc. and Betta Pharmaceuticals, Co., Ltd (Filed With SEC on August 5, 2022)

First Amendment to Loan and Security Agreement, dated June 2, 2022, by and among EyePoint Pharmaceuticals, Inc., EyePoint Pharmaceuticals US, Inc., Icon Bioscience, Inc. and... (Filed With SEC on August 5, 2022)

Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 14, 2022)

Fourth Amendment to Lease, dated March 8, 2022, between GRE Riverworks, LLC and EyePoint Pharmaceuticals, Inc (Filed With SEC on March 14, 2022)

Commercial Alliance Expansion Term Letter Agreement dated December 6, 2021 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC (Filed With SEC on March 14, 2022)

Loan and Security Agreement, dated March 9, 2022, among EyePoint Pharmaceuticals, Inc., EyePoint Pharmaceuticals US, Inc., Icon Bioscience, Inc. and Silicon Valley Bank (Filed With SEC on March 14, 2022)

Employment Agreement, dated January 10, 2022, by and between EyePoint Pharmaceuticals, Inc. and Michael, C. Pine (Filed With SEC on January 10, 2022)

Underwriting Agreement, dated November 16, 2021, by and among EyePoint Pharmaceuticals, Inc. and Cowen and Company, LLC and Guggenheim Securities, LLC (Filed With SEC on November 19, 2021)

Form of Pre-Funded Warrant to Purchase Common Stock (Filed With SEC on November 19, 2021)

EyePoint Pharmaceuticals, Inc. 2016 Long-Term Incentive Plan, as amended (Filed With SEC on June 24, 2021)

EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, as amended (Filed With SEC on June 24, 2021)

Third Amendment to Lease, dated April 5, 2021, between GRE Riverworks, LLC and EyePoint Pharmaceuticals, Inc (Filed With SEC on May 5, 2021)

Amendment No. 3 and Waiver To Term Loan Agreement, dated May 3, 2021, among EyePoint Pharmaceuticals, Inc. as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience,... (Filed With SEC on May 5, 2021)

Description of Securities of EyePoint Pharmaceuticals, Inc (Filed With SEC on March 12, 2021)

Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on March 12, 2021)

Amendment One to the Commercial Alliance Agreement dated November 12, 2020 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC (Filed With SEC on March 12, 2021)

Royalty Purchase Agreement, dated December 17, 2020, by and between EyePoint Pharmaceuticals, Inc. and SWK Funding, LLC (Filed With SEC on March 12, 2021)

Underwriting Agreement, dated February 1, 2021, by and among EyePoint Pharmaceuticals, Inc. and Cowen and Company, LLC and Guggenheim Securities, LLC (Filed With SEC on February 3, 2021)

First Amendment to Share Purchase Agreement, dated February 1, 2021, by and between EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics (Filed With SEC on February 3, 2021)

Share Purchase Agreement, dated December 31, 2020, by and between EyePoint Pharmaceuticals, Inc. and Ocumension Therapeutics (Filed With SEC on January 4, 2021)

Voting and Investor Rights Agreement, dated December 31, 2020, by and among EyePoint Pharmaceuticals, Inc., Ocumension Therapeutics, and EW Healthcare Partners, L.P. and EW... (Filed With SEC on January 4, 2021)

Commercial Alliance Agreement, dated as of August 1, 2020 between EyePoint Pharmaceuticals, Inc. and ImprimisRx, LLC (Filed With SEC on November 6, 2020)

Amendment No. 2 and Waiver To Term Loan Agreement, dated October 8, 2020, among EyePoint Pharmaceuticals, Inc. as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience,... (Filed With SEC on October 8, 2020)

Controlled Equity OfferingSM Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald & Co (Filed With SEC on August 5, 2020)

Description of Securities of EyePoint Pharmaceuticals, Inc (Filed With SEC on March 16, 2020)

Exclusive License Agreement, dated February 3, 2020, between EyePoint Pharmaceuticals, Inc. and Equinox Science, LLC (Filed With SEC on March 16, 2020)

Underwriting Agreement, dated February 21, 2020, by and between EyePoint Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on February 24, 2020)

Waiver To Term Loan Agreement, dated November 19, 2019, among EyePoint Pharmaceuticals, as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as subsidiary... (Filed With SEC on November 22, 2019)

Employment Agreement, dated November 14, 2019, by and between EyePoint Pharmaceuticals, Inc. and George Elston (Filed With SEC on November 19, 2019)

Employment Agreement between EyePoint Pharmaceuticals, Inc. and Scott Jones, dated May 30, 2019 (Filed With SEC on August 7, 2019)

Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on August 7, 2019)

EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan (Filed With SEC on June 28, 2019)

Amendment No. 1 to EyePoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan (Filed With SEC on June 28, 2019)

EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on June 28, 2019)

Underwriting Agreement, dated March 28, 2019, by and between EyePoint Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on April 1, 2019)

Fee Letter, dated February 13, 2019, by and between EyePoint Pharmaceuticals, Inc. and CRG Servicing LLC (Filed With SEC on February 19, 2019)

Term Loan Agreement, dated February 13, 2019, among EyePoint Pharmaceuticals, Inc., as Borrower, EyePoint Pharmaceuticals US, Inc. and Icon Bioscience, Inc., as Subsidiary... (Filed With SEC on February 19, 2019)

At Market Issuance Sales Agreement, dated January 18, 2019, between EyePoint Pharmaceuticals, Inc. and B. Riley FBR, Inc (Filed With SEC on January 18, 2019)

Stock Option Award Agreement, dated May 14, 2018, by and between EyePoint Pharmaceuticals, Inc. and Leonard M. Blum (Filed With SEC on November 9, 2018)

Stock Option Award Agreement, dated August 1, 2018, by and between EyePoint Pharmaceuticals, Inc. and David Price (Filed With SEC on November 9, 2018)

Performance Stock Unit Award Agreement, dated August 1, 2018, by and between EyePoint Pharmaceuticals, Inc. and David Price (Filed With SEC on November 9, 2018)

Stock Option Award Agreement, dated August 14, 2018, by and between EyePoint Pharmaceuticals, Inc. and John Weet (Filed With SEC on November 9, 2018)

Employment Agreement, dated May 11, 2018, by and between EyePoint Pharmaceuticals, Inc. and Leonard Blum (Filed With SEC on September 18, 2018)

Form of Stock Option Award Agreement for Inducement grants to executive officers (Filed With SEC on September 18, 2018)

Form of Indemnification Agreement between EyePoint Pharmaceuticals, Inc. and its officers and directors (Filed With SEC on September 18, 2018)

EyePoint Pharmaceutical Short Term Incentive Plan (Filed With SEC on September 18, 2018)

First Amendment of Lease, dated February 6, 2014, between Farley White Aetna Mills, LLC and pSivida Corp (Filed With SEC on September 18, 2018)

Second Amendment of Lease, dated May 14, 2018, between Whetstone Riverworks Holdings, LLC and EyePoint Pharmaceuticals, Inc (Filed With SEC on September 18, 2018)

Employment Agreement, dated August 1, 2018, by and between EyePoint Pharmaceuticals, Inc. and David Price (Filed With SEC on August 3, 2018)

Form of Warrant to Purchase Common Stock of EyePoint Pharmaceuticals, Inc., issued June 25, 2018, to the Second Tranche Investors (Filed With SEC on June 27, 2018)

Second Registration Rights Agreement, dated as of June 25, 2018, by and among EyePoint Pharmaceuticals, Inc. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P.... (Filed With SEC on June 27, 2018)

Short Term Incentive Plan (Filed With SEC on May 10, 2018)

Employment Agreement, dated March 27, 2018, by and between Dario Paggiarino and EyePoint Pharmaceuticals, Inc (Filed With SEC on May 10, 2018)

Warrant to Purchase Common Stock of pSivida Corp., issued March 28, 2018, to SWK Funding LLC (Filed With SEC on March 29, 2018)

Securities Purchase Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P (Filed With SEC on March 29, 2018)

Second Securities Purchase Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P. and each other... (Filed With SEC on March 29, 2018)

Registration Rights Agreement, dated as of March 28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P (Filed With SEC on March 29, 2018)

Credit Agreement, dated as of March 28, 2018, among pSivida Corp., SWK Funding LLC and the financial institutions party thereto from time to time as lenders (Filed With SEC on March 29, 2018)

Agreement and Plan of Merger, dated March 28, 2018, by and among pSivida Corp., Oculus Merger Sub, Inc., Icon Bioscience, Inc. and Shareholder Representative Services LLC (Filed With SEC on March 29, 2018)

Form of Stock Option Certificate for grants to executive officers under the pSivida Corp. 2016 Long Term Incentive Plan, as amended (Filed With SEC on February 8, 2018)

Form of Deferred Stock Unit Award for grants to non-executive directors under the pSivida Corp. 2016 Long Term Incentive Plan, as amended (Filed With SEC on February 8, 2018)

Employment Agreement, between pSivida Corp. and Dario Paggiarino, dated July 7, 2016 (Filed With SEC on September 13, 2017)

Form of Restricted Stock Unit Award for grants to executive officers under the pSivida Corp. 2016 Long Term Incentive Plan, as amended (Filed With SEC on September 13, 2017)

Form of Performance-Based Stock Unit Award for grants under the pSivida Corp. 2016 Long Term Incentive Plan, as amended (Filed With SEC on September 13, 2017)

Second Amended and Restated Collaboration Agreement by and between pSivida US Inc. and Alimera Sciences, Inc. dated July 10, 2017 (Filed With SEC on September 13, 2017)

Agreement, dated April 11, 2017, by and between pSivida Corp., pSiMedica Limited and Pfizer, Inc (Filed With SEC on September 13, 2017)

pSivida Short Term Incentive Plan (Filed With SEC on June 30, 2017)

PSIVIDA CORP. 2016 LONGTERM INCENTIVE PLAN (Filed With SEC on February 9, 2017)

PSIVIDA CORP. CommonStock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on February 8, 2017)

pSivida 480 Pleasant Street Suite B300 Watertown, MA 02472 (Filed With SEC on January 10, 2017)

PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT INDUCEMENT AWARD (Filed With SEC on December 23, 2016)

PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on December 23, 2016)

- 2 - (Filed With SEC on November 8, 2016)

PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT INDUCEMENT AWARD (Filed With SEC on November 8, 2016)

Nonstatutory Stock Option Inducement Award (Filed With SEC on November 8, 2016)

- 2 - (Filed With SEC on November 8, 2016)

PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on November 8, 2016)

Nonstatutory Stock Option Granted Under pSivida Corp. 2008 Incentive Plan (Filed With SEC on November 8, 2016)

AGREEMENT (Filed With SEC on November 8, 2016)

PSIVIDA CORP. 4,000,000Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 8, 2016)

PSIVIDA CORP. (Filed With SEC on September 10, 2015)

pSivida Corp. 2008 INCENTIVE PLAN (as amended in 2009) (Filed With SEC on September 10, 2015)

PSIVIDA CORP. CommonStock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on December 20, 2013)

LEASE Landlord: Farley White Aetna Mills, LLC Tenant: pSivida Corp. Date of Lease: As of November 1, 2013 TABLE OF CONTENTS (Filed With SEC on November 13, 2013)

PSIVIDA CORP. 3,494,550 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on July 19, 2013)

Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on August 2, 2012)

COMMON STOCK PURCHASE WARRANT PSIVIDA CORP. (Filed With SEC on August 2, 2012)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on September 13, 2011)

pSivida Corp. 400 Pleasant Street Watertown, MA 02472 (Filed With SEC on December 21, 2010)

CONFIDENTIAL TREATMENT REQUESTED (Filed With SEC on April 26, 2010)

pSivida KEY EMPLOYEE ANNUAL BONUS PLAN (Filed With SEC on February 12, 2010)

SECOND AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on September 25, 2009)

EXHIBIT A RELEASE OF CLAIMS (Filed With SEC on May 13, 2009)

[Nonstatutory] Stock Option Granted Under pSivida Corp. 2008 Incentive Plan (Filed With SEC on February 11, 2009)

Nonstatutory Stock Option Granted Under pSivida Corp. 2008 Incentive Plan (Filed With SEC on September 26, 2008)

Nonstatutory Stock Option Granted Under pSivida Corp. 2008 Incentive Plan (Filed With SEC on September 10, 2008)

AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on May 12, 2008)

Category

Industry

Companies

Contracts

EyePoint Pharmaceuticals, Inc. Contracts & Agreements